Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Psoriasis | 38 | 2021 | 1739 | 5.62 | Why? |
| Dermatologic Agents | 11 | 2020 | 489 | 2.13 | Why? |
| Dermatologists | 4 | 2020 | 435 | 1.22 | Why? |
| Arthritis, Psoriatic | 8 | 2021 | 625 | 1.13 | Why? |
| Biological Products | 7 | 2021 | 2331 | 0.85 | Why? |
| Metabolic Syndrome | 3 | 2019 | 810 | 0.84 | Why? |
| Skin Diseases | 5 | 2020 | 2509 | 0.83 | Why? |
| Stevens-Johnson Syndrome | 1 | 2021 | 129 | 0.74 | Why? |
| Penile Diseases | 1 | 2018 | 15 | 0.73 | Why? |
| Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 | 1 | 2017 | 31 | 0.71 | Why? |
| Pyoderma Gangrenosum | 1 | 2018 | 41 | 0.70 | Why? |
| Folic Acid | 1 | 2019 | 172 | 0.68 | Why? |
| Aluminum | 1 | 2017 | 71 | 0.67 | Why? |
| Infliximab | 2 | 2017 | 502 | 0.60 | Why? |
| Biosimilar Pharmaceuticals | 1 | 2017 | 205 | 0.55 | Why? |
| Eczema | 1 | 2017 | 227 | 0.53 | Why? |
| Cyclosporine | 1 | 2017 | 449 | 0.52 | Why? |
| Biological Therapy | 4 | 2021 | 456 | 0.50 | Why? |
| Prenatal Exposure Delayed Effects | 1 | 2017 | 319 | 0.49 | Why? |
| Drug Eruptions | 1 | 2017 | 319 | 0.49 | Why? |
| Dermatology | 2 | 2019 | 1999 | 0.49 | Why? |
| Melanoma | 1 | 2021 | 1229 | 0.41 | Why? |
| Antibodies, Monoclonal | 6 | 2019 | 8041 | 0.36 | Why? |
| Weight Gain | 1 | 2013 | 552 | 0.35 | Why? |
| Skin Neoplasms | 1 | 2021 | 1679 | 0.34 | Why? |
| Public Opinion | 1 | 2017 | 1165 | 0.33 | Why? |
| Hospitalization | 4 | 2020 | 54280 | 0.31 | Why? |
| Adalimumab | 2 | 2020 | 389 | 0.28 | Why? |
| Immunosuppressive Agents | 3 | 2020 | 6331 | 0.28 | Why? |
| Virus Diseases | 1 | 2021 | 3779 | 0.26 | Why? |
| Transplant Recipients | 1 | 2020 | 4982 | 0.26 | Why? |
| Practice Patterns, Physicians' | 2 | 2021 | 4927 | 0.24 | Why? |
| Antibodies, Monoclonal, Humanized | 6 | 2021 | 9335 | 0.22 | Why? |
| Italy | 10 | 2021 | 38444 | 0.22 | Why? |
| Betamethasone | 2 | 2017 | 63 | 0.21 | Why? |
| Adipokines | 2 | 2019 | 87 | 0.21 | Why? |
| Calcitriol | 2 | 2017 | 84 | 0.21 | Why? |
| Humans | 55 | 2021 | 930598 | 0.20 | Why? |
| Body Mass Index | 1 | 2013 | 4306 | 0.20 | Why? |
| Interleukin-17 | 3 | 2021 | 602 | 0.20 | Why? |
| Joint Diseases | 1 | 2021 | 122 | 0.20 | Why? |
| Darier Disease | 1 | 2018 | 4 | 0.19 | Why? |
| Keratolytic Agents | 1 | 2017 | 16 | 0.18 | Why? |
| Homocysteine | 1 | 2019 | 83 | 0.18 | Why? |
| Wnt Signaling Pathway | 1 | 2018 | 87 | 0.18 | Why? |
| Dermatitis | 1 | 2021 | 188 | 0.18 | Why? |
| Injections, Intra-Articular | 1 | 2018 | 104 | 0.17 | Why? |
| Isotretinoin | 1 | 2018 | 58 | 0.17 | Why? |
| Vitamin B 12 | 1 | 2019 | 132 | 0.17 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2017 | 1454 | 0.17 | Why? |
| Glycation End Products, Advanced | 1 | 2017 | 72 | 0.17 | Why? |
| Patch Tests | 1 | 2017 | 114 | 0.16 | Why? |
| Alcohol-Related Disorders | 1 | 2017 | 84 | 0.16 | Why? |
| Azathioprine | 1 | 2018 | 161 | 0.16 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.16 | Why? |
| Isoniazid | 1 | 2017 | 105 | 0.16 | Why? |
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 245 | 0.16 | Why? |
| Etanercept | 1 | 2017 | 162 | 0.16 | Why? |
| Lymphoproliferative Disorders | 1 | 2017 | 110 | 0.15 | Why? |
| Hidradenitis Suppurativa | 1 | 2020 | 309 | 0.15 | Why? |
| Spondylarthritis | 1 | 2018 | 174 | 0.15 | Why? |
| Nail Diseases | 1 | 2018 | 142 | 0.14 | Why? |
| Norway | 1 | 2019 | 1004 | 0.14 | Why? |
| Thalidomide | 1 | 2017 | 247 | 0.14 | Why? |
| Skin Diseases, Viral | 1 | 2021 | 436 | 0.14 | Why? |
| Severity of Illness Index | 10 | 2021 | 48226 | 0.14 | Why? |
| Registries | 3 | 2020 | 12327 | 0.14 | Why? |
| Female | 24 | 2021 | 380317 | 0.13 | Why? |
| Biological Factors | 1 | 2017 | 276 | 0.13 | Why? |
| Rheumatologists | 1 | 2018 | 346 | 0.13 | Why? |
| Wound Healing | 1 | 2018 | 424 | 0.13 | Why? |
| Prednisone | 1 | 2018 | 652 | 0.13 | Why? |
| Stress, Psychological | 1 | 2017 | 10231 | 0.13 | Why? |
| Treatment Outcome | 7 | 2021 | 51732 | 0.13 | Why? |
| Male | 23 | 2021 | 367725 | 0.13 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.12 | Why? |
| Latent Tuberculosis | 1 | 2017 | 324 | 0.12 | Why? |
| Adipose Tissue | 1 | 2017 | 612 | 0.12 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.12 | Why? |
| Incidence | 4 | 2021 | 25622 | 0.11 | Why? |
| Aged | 16 | 2021 | 215776 | 0.11 | Why? |
| Ustekinumab | 1 | 2013 | 216 | 0.11 | Why? |
| Medication Adherence | 2 | 2017 | 1270 | 0.11 | Why? |
| Inflammation | 3 | 2018 | 13255 | 0.11 | Why? |
| Risk Assessment | 5 | 2021 | 25439 | 0.11 | Why? |
| Chronic Disease | 3 | 2021 | 5139 | 0.10 | Why? |
| Adrenal Cortex Hormones | 2 | 2018 | 6537 | 0.10 | Why? |
| Adult | 15 | 2021 | 244371 | 0.10 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.09 | Why? |
| Risk | 2 | 2021 | 5288 | 0.09 | Why? |
| Hepatitis B | 1 | 2017 | 888 | 0.09 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.09 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.09 | Why? |
| Obesity | 2 | 2019 | 7388 | 0.09 | Why? |
| Retrospective Studies | 7 | 2020 | 105322 | 0.09 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.08 | Why? |
| Immunotherapy | 1 | 2021 | 2421 | 0.08 | Why? |
| Drug Therapy, Combination | 2 | 2018 | 7268 | 0.08 | Why? |
| Body Weight | 1 | 2013 | 1074 | 0.08 | Why? |
| Cognitive Dysfunction | 1 | 2018 | 1389 | 0.08 | Why? |
| Surveys and Questionnaires | 3 | 2019 | 43792 | 0.08 | Why? |
| Administration, Cutaneous | 2 | 2017 | 229 | 0.08 | Why? |
| Electronic Health Records | 1 | 2020 | 3492 | 0.08 | Why? |
| Oxidative Stress | 1 | 2017 | 2050 | 0.08 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.08 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.07 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.07 | Why? |
| Self Report | 1 | 2017 | 3802 | 0.07 | Why? |
| Diet | 1 | 2017 | 2052 | 0.07 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.07 | Why? |
| Referral and Consultation | 2 | 2018 | 4816 | 0.07 | Why? |
| Dementia | 1 | 2018 | 1861 | 0.07 | Why? |
| Pandemics | 9 | 2021 | 389249 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2018 | 1996 | 0.07 | Why? |
| Methotrexate | 2 | 2019 | 471 | 0.07 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.07 | Why? |
| Ultrasonography | 2 | 2018 | 4409 | 0.07 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.06 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.06 | Why? |
| Quality of Life | 3 | 2019 | 9820 | 0.06 | Why? |
| Prevalence | 4 | 2018 | 25773 | 0.06 | Why? |
| Prospective Studies | 3 | 2019 | 43301 | 0.06 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.06 | Why? |
| Receptors, Interleukin | 1 | 2021 | 83 | 0.05 | Why? |
| Kidney Transplantation | 1 | 2020 | 5397 | 0.05 | Why? |
| Age of Onset | 1 | 2021 | 557 | 0.05 | Why? |
| Adipose Tissue, White | 1 | 2017 | 30 | 0.04 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.04 | Why? |
| Tuberculosis, Pleural | 1 | 2017 | 22 | 0.04 | Why? |
| Clinical Studies as Topic | 1 | 2018 | 118 | 0.04 | Why? |
| Anti-Inflammatory Agents | 1 | 2017 | 6153 | 0.04 | Why? |
| Hyperpigmentation | 1 | 2018 | 42 | 0.04 | Why? |
| Drug Combinations | 2 | 2017 | 3852 | 0.04 | Why? |
| Phototherapy | 1 | 2019 | 138 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.04 | Why? |
| Physician-Patient Relations | 2 | 2017 | 1266 | 0.04 | Why? |
| Tuberculin Test | 1 | 2017 | 141 | 0.04 | Why? |
| Adolescent | 5 | 2017 | 86841 | 0.04 | Why? |
| Nails | 1 | 2018 | 143 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.04 | Why? |
| Pruritus | 1 | 2018 | 215 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Skin | 2 | 2018 | 2096 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Hyperlipidemias | 1 | 2017 | 290 | 0.04 | Why? |
| Uveitis | 1 | 2018 | 233 | 0.04 | Why? |
| Patient Satisfaction | 2 | 2017 | 2517 | 0.03 | Why? |
| Remission Induction | 1 | 2018 | 950 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Patient Care Planning | 1 | 2018 | 582 | 0.03 | Why? |
| Sex Factors | 2 | 2020 | 11014 | 0.03 | Why? |
| Reactive Oxygen Species | 1 | 2017 | 1136 | 0.03 | Why? |
| Information Storage and Retrieval | 1 | 2017 | 644 | 0.03 | Why? |
| Neuroimaging | 1 | 2018 | 1106 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2018 | 23402 | 0.03 | Why? |
| Antitubercular Agents | 1 | 2017 | 775 | 0.03 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2021 | 2483 | 0.03 | Why? |
| Observational Studies as Topic | 1 | 2018 | 1887 | 0.03 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.03 | Why? |
| Liver Function Tests | 1 | 2017 | 1325 | 0.03 | Why? |
| Interdisciplinary Communication | 1 | 2018 | 1425 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2017 | 2324 | 0.03 | Why? |
| Chilblains | 1 | 2021 | 1156 | 0.02 | Why? |
| Sex Distribution | 1 | 2017 | 2083 | 0.02 | Why? |
| Denmark | 1 | 2017 | 2654 | 0.02 | Why? |
| Pain | 1 | 2017 | 1084 | 0.02 | Why? |
| Joints | 1 | 2010 | 97 | 0.02 | Why? |
| Cognition | 1 | 2018 | 1394 | 0.02 | Why? |
| Crohn Disease | 1 | 2018 | 959 | 0.02 | Why? |
| Colitis, Ulcerative | 1 | 2018 | 1037 | 0.02 | Why? |
| Magnetic Resonance Imaging | 2 | 2018 | 6551 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Age Distribution | 1 | 2017 | 3567 | 0.02 | Why? |
| Hyperglycemia | 1 | 2017 | 1363 | 0.02 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.02 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.02 | Why? |
| Patient Care Team | 1 | 2018 | 3556 | 0.02 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.02 | Why? |
| Child | 3 | 2017 | 70012 | 0.02 | Why? |
| Antirheumatic Agents | 1 | 2017 | 3023 | 0.01 | Why? |
| Tuberculosis | 1 | 2017 | 2895 | 0.01 | Why? |
| Brain | 1 | 2018 | 5133 | 0.01 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Cytokines | 1 | 2019 | 15010 | 0.01 | Why? |
| Viral Load | 1 | 2017 | 15850 | 0.01 | Why? |
| Diagnosis, Differential | 1 | 2010 | 7220 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| Time Factors | 1 | 2017 | 31397 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2021 | 88759 | 0.01 | Why? |
Gisondi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(194)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(223)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_